DiscGenics is a privately held, clinical stage regenerative medicine company focused on developing cell therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of intervertebral disc cells to develop therapies that we believe will have a profound impact on millions suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic (off-the-shelf), injectable cell therapy that utilizes proprietary Discogenic Cells to offer a non-surgical, potentially regenerative solution for the treatment of patients with degenerative disc disease (DDD). The Company is currently conducting a 60-patient Phase I/II clinical study to evaluate the safety and preliminary efficacy of IDCT in subjects with single-level symptomatic lumbar DDD.